Relay Therapeutics (RLAY) Enterprise Value (2020 - 2025)
Relay Therapeutics (RLAY) has disclosed Enterprise Value for 6 consecutive years, with -$84.0 million as the latest value for Q4 2025.
- On a quarterly basis, Enterprise Value rose 32.4% to -$84.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$84.0 million, a 32.4% increase, with the full-year FY2025 number at -$84.0 million, up 32.4% from a year prior.
- Enterprise Value was -$84.0 million for Q4 2025 at Relay Therapeutics, up from -$91.6 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$84.0 million in Q4 2025 to a low of -$354.6 million in Q3 2022.
- A 5-year average of -$165.7 million and a median of -$148.6 million in 2023 define the central range for Enterprise Value.
- Biggest YoY gain for Enterprise Value was 59.13% in 2021; the steepest drop was 273.49% in 2021.
- Relay Therapeutics' Enterprise Value stood at -$280.1 million in 2021, then surged by 45.81% to -$151.8 million in 2022, then rose by 5.31% to -$143.7 million in 2023, then increased by 13.53% to -$124.3 million in 2024, then soared by 32.4% to -$84.0 million in 2025.
- Per Business Quant, the three most recent readings for RLAY's Enterprise Value are -$84.0 million (Q4 2025), -$91.6 million (Q3 2025), and -$113.9 million (Q2 2025).